Recruit Rockstars Podcast #367: How His VC-Backed Team Made Drug Development Faster

When creating new drugs, it’s often difficult to find enough patients for clinical trials.

And that limits the number of trials you can run.

Which slows down drug development. And costs lives.

Charles Fisher is out to change all that.

He’s CEO of Unlearn.AI

Based in San Francisco, Unlearn helps biopharma companies develop drugs more efficiently by leveraging AI to reduce the number of patients required for placebo controls in clinical trials.

In fact, Unlearn.AI enables clinical trials that are twice as fast, require fewer patients, produce better evidence about efficacy, and in which fewer patients need to be given placebos.

Last week, the company announced a major venture investment from Epic Ventures, Alumni Ventures Group, and the global Pharma company Eisai

Charles & his team are creating the first commercial product providing AI-derived Intelligent Control Arms to increase the statistical power of clinical trials, and accelerate study timelines in Alzheimer’s Disease.

In this 20-minute conversation, he reveals how he’s scaling the team.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

Part 3: Innovation in Clinical Research: AI-based Drug Development Tools and the Regulatory Landscape‍

Webinars

Part 2: Faster, More Efficient Trials: Novel Trial Designs using Digital Twins‍

Webinars

Part 1: AI, Digital Twins, and the Future of Clinical Research‍

Learn about how Digital Twins are created and how they are incorporated into clinical trials to increase power, accelerate timelines, and enable patient level insights.
Watch an overview of specific use cases for Digital Twins and learn how novel trial designs with Digital Twins enable smaller trials that maintain their power.
Watch a panel discussion on the regulatory landscape where experts share perspectives on the future of AI-based drug development tools like Digital Twins.